Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 6/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.37 |
| ▸ | IL1B | P01584 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 3/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.34 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30101125 | 0.74 | KAT2B (0.42) | EHMT2IL1B | |
| SCHEMBL30101082 | 0.74 | KAT2B (0.42) | EHMT2IL1B | |
| SCHEMBL30101112 | 0.74 | PRKCI (0.40) | EHMT2BRD4CHEK2IL1BPRKCI | |
| SCHEMBL30108831 | 0.72 | PRKCI (0.40) | EHMT2BRD4CHEK2IL1BPRKCI | |
| SCHEMBL30108649 | 0.72 | PRKCI (0.40) | EHMT2BRD4CHEK2IL1BPRKCI | |
| SCHEMBL30101023 | 0.72 | NLRP3 (0.45) | IL1B | |
| Hydrochloric Acid SCHEMBL31367806 | 0.67 | BRD4 (0.44) | EHMT2BRD4CHEK2IL1BCHEK1 | |
| SCHEMBL31021521 | 0.63 | IL1B (0.55) | EHMT2BRD4CHEK2IL1BPRKCI | |
| SCHEMBL30259588 | 0.63 | KDM4E (0.61) | BRD4PRKCZ | |
| SCHEMBL31367809 | 0.62 | CHEK1 (0.45) | IL1BCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022253326-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | 药捷安康(南京)科技股份有限公司 | 2022-12-08 | — | — | WO | disclosed |